Please select the eligibility criteria that correspond to the clinical trial below.
Title: Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors.
Brief Summary: The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.


Options:
A: Inclusion Criteria:

* Undergoing In-vitro fertilization (IVF) treatment
* Number of previous failed embryo transfers ≤ 2
* Permanent living in Viet Nam
* Ovarian hyperstimulation with Gonadotropin releasing hormone (GnRH) antagonist protocol
* Eligible for embryo transfer (ET) on day 3
* Having at least one top-quality embryo on day 3.
* Number of embryos transferred ≤ 2
* Willing to participate in the study
* Not to participate in another IVF study at the same time

Exclusion Criteria:

* women with polycystic ovary syndrome
* In vitro maturation (IVM) cycles
* Oocyte donation cycles
* Using GnRH agonist for triggering
B: Inclusion Criteria:

* Oocyte donors included in the oocyte donation program of Clinica EUGIN.
* 1st oocyte donation cycle at Clínica EUGIN.

Exclusion Criteria:

* Polycistic Ovarian syndrome (PCOs).
* Estradiol levels on day 2 of menstrual cycle \>70 pg/ml.
* Hormone treatments up to 3 months before the oocyte donation cycle.
* Medical contraindication to the treatments used in the study
C: Inclusion Criteria:

* Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
* Women who have ≥1 years history of infertility;
* Women aged ≥20 and \<35 years old;
* Women with body weight ≥40kg;
* Women who have at least one of the following indications for IVF or ICSI:

  1. Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
  2. Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
  3. Male factors: oligoasthenozoospermia, obstructive azoospermia;
* Women who are undergoing their first cycle of IVF or ICSI;
* Women who retrieved oocytes number \> 3;
* Women who are capable of giving informed consent.

Exclusion Criteria:

* Women who underwent unilateral ovariectomy;
* Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
* Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
* Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
* Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
* Women who has developed severe OHSS before oocyte pick-up day;
* Women with retrieved oocytes number ≤3;
* Women who are unable to comply with the study procedures.
D: Inclusion Criteria:

* Age between 18-35 years (both included)
* Regular Menses (between 25-35 days)
* Absence of physical and psychic pathologies at the time of oocyte donation
* BMI: 18-28 kg(m2 at the time of oocyte donation.
* Other criteria to comply with:

  i. With no relevant personal or family medical history ii. Signing of Informed Consent iii. From a medical point of view:
  1. Healthy ovaries and uterus, with no organic pathology
  2. Ovaries without polycystic aspect
  3. Antral Follicle Count \> 12 in the sum of both ovaries
  4. Normal Karyotype
  5. Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis)
  6. Results within range of general analysis of hemogram, hemostasia y biochemistry.

     Exclusion Criteria:
* Any systemic or metabolic disorder which contraindicate the use of Gonadotrophines
* Medical background of Trombophlebitis or thromboembolic phenomena or Arterial Hypertension
* Severe hepatic insufficiency, cardiovascular illness
* Suspicion or evidence of malignity of mamarian glands or other hormone dependant genital organs
* Known infection of Hepatitis B Virus; Hepatitis C Virus or VIH Virus
* Known hypersensitivity to PMA or its excipients
* Any reason or cause which excluede from the oocyte donation program
* Participation in another clinical trial in the two months prior to the inclusion on this study

Answer: D